Literature DB >> 15142200

Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough.

J Hammer1, B Schmidt.   

Abstract

BACKGROUND: Twice-daily dosing is increasingly used to improve gastric acid control, although not all proton-pump inhibitors are more effective when doses are split. Standard dose esomeprazole provides better gastric acid control than other standard dose proton-pump inhibitors. AIMS: To compare the effect of standard dose esomeprazole (1 x 40 mg) with 20 mg b.d. on gastric acidity.
METHODS: Thirteen healthy subjects participated in this crossover study, receiving esomeprazole 2 x 20 mg and 1 x 40 mg for 7 days in random order with a washout period of at least 7 days. Gastric 24-h pH was measured on days 1, 2 and 6.
RESULTS: Median gastric 24-h pH was higher during 2 x 20 mg esomeprazole on day 2 (P < 0.01), no differences were detected on day 6. Night-time gastric acid suppression was significantly improved by 2 x 20 mg esomeprazole on all study days (P < 0.05). Nocturnal acid breakthrough was observed on all study days in subjects receiving 1 x 40 mg, but in only 85% (first night), 64% (second night), and 45% of subjects (sixth night) with 2 x 20 mg (P < 0.05).
CONCLUSION: Splitting the esomeprazole dose improves initial acid suppression, this effect starts at the first night. Maximal benefit is achieved on day 2, while the effect on night-time acid control is detectable during the entire first week of treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15142200     DOI: 10.1111/j.1365-2036.2004.01949.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  11 in total

1.  Nocturnal acid breakthrough on proton pump inhibitor therapy: to treat or not to treat.

Authors:  Philip O Katz; Robert S Dudnick
Journal:  Curr Treat Options Gastroenterol       Date:  2008-02

2.  Barrett's Esophagus, fundoplication, and cancer.

Authors:  David I Watson; George C Mayne; Damian J Hussey
Journal:  World J Surg       Date:  2007-03       Impact factor: 3.352

Review 3.  Nocturnal acid breakthrough - approach to management.

Authors:  Radu Tutuian; Donald O Castell
Journal:  MedGenMed       Date:  2004-10-26

Review 4.  Optimising acid inhibition treatment.

Authors:  Fernando Gomollón; Xavier Calvet
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 5.  Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults.

Authors:  Kate McKeage; Stephanie K A Blick; Jamie D Croxtall; Katherine A Lyseng-Williamson; Gillian M Keating
Journal:  Drugs       Date:  2008       Impact factor: 9.546

6.  Quantification of dental erosions in patients with GERD using optical coherence tomography before and after double-blind, randomized treatment with esomeprazole or placebo.

Authors:  Clive H Wilder-Smith; Petra Wilder-Smith; Hilari Kawakami-Wong; Julia Voronets; Kathy Osann; Adrian Lussi
Journal:  Am J Gastroenterol       Date:  2009-08-04       Impact factor: 10.864

Review 7.  Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH.

Authors:  Julia Kirchheiner; Silke Glatt; Uwe Fuhr; Ulrich Klotz; Ingolf Meineke; Thomas Seufferlein; Jürgen Brockmöller
Journal:  Eur J Clin Pharmacol       Date:  2008-10-17       Impact factor: 2.953

8.  Relationship between esomeprazole dose and timing to heartburn resolution in selected patients with gastroesophageal reflux disease.

Authors:  Roy C Orlando; Sherry Liu; Marta Illueca
Journal:  Clin Exp Gastroenterol       Date:  2010-09-06

9.  Evaluation of the pharmacokinetics of trazpiroben (TAK-906) in the presence and absence of the proton pump inhibitor esomeprazole.

Authors:  Jatinder Kaur Mukker; George Dukes; Lisi Wang; Susanna Huh; Polyna Khudyakov; Mitsuhiro Nishihara; Chunlin Chen
Journal:  Clin Transl Sci       Date:  2022-02-26       Impact factor: 4.438

10.  Can Nocturnal Acid-breakthrough Be Reduced by Long-acting Proton Pump Inhibitors?

Authors:  Hye Kyung Jeon; Gwang Ha Kim
Journal:  J Neurogastroenterol Motil       Date:  2017-04-30       Impact factor: 4.924

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.